Navigation Links
EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery

PROVIDENCE, R.I., Nov. 26 /PRNewswire/ -- EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine. NIAID will provide EpiVax with $390,000 over two years for the proposed research.

"The recent failure of the investigational HIV vaccine tested in the Phase II clinical trial known as STEP is a strong indicator that more traditional approaches to vaccine design and delivery are simply not going to work for HIV. That's why the EpiVax brand of "outside the box" thinking was funded; the world is looking for safer, more effective ways to prevent AIDS," said Dr. Annie De Groot, CEO and CSO of the company. "We are especially aware of the need for such a vaccine as we approach World AIDS Day, a time when our thoughts turn to the 50 million people who have been infected with HIV and the 20 million who have already died from AIDS."

Using the grant funding from the NIH, EpiVax will develop a pro-inflammatory and non-tolerogenic HIV vaccine delivery system based on the dendritic cell targeting anti-DEC-205 antibody. The success of anti-DEC-205 as a vaccine carrier is dependent on co-administration of non-specific dendritic cell maturation factors such as CD40-ligand. In their absence, anti-DEC-205 induces antigen-specific tolerance rather than immunity. EpiVax reasons that regulatory T-cell epitopes contained in anti-DEC-205 promote a tolerogenic reaction that is only overcome through the coadministration of clinically dangerous or untested non-specific immuno-stimulators. This idea is based on EpiVax' discovery of a set of natural regulatory T-cell epitopes derived from human immunoglobulins that induce tolerance by stimulating regulatory T cells. EpiVax has already verified experimentally that these epitopes cause antigen-specific expansion of regulatory T cells and suppress inflammatory immune responses.

The NIH award will enable EpiVax to develop a modified pro-inflammatory and non-tolerogenic anti-DEC-205 antibody. Modification of regulatory T-cell epitopes is expected to significantly diminish tolerogenicity, enabling use of anti-DEC-205 as a stand-alone HIV antigen delivery system that obviates the dangers associated with non-specific activation of the immune system.

Epitope modification is an immunomodulatory approach EpiVax previously developed to reduce immunogenicity of protein therapeutics. Here, EpiVax will substitute key amino acids in the regulatory T-cell epitopes with those that are experimentally shown to interfere with MHC binding to reduce tolerogenicity.

About HIV

Vaccines According to the World Health Organization, "The development of a safe and effective vaccine is hampered by the high genetic variability of HIV, the lack of knowledge of immune correlates of protection, the absence of relevant and predictive animal models, and the complexity of the implementation of efficacy trials, especially in developing countries."

About EpiVax

This grant award is the 5th consecutive NIH or foundation award granted to EpiVax in the last year, for a total of more than $ 2.5M. EpiVax, Inc. is dedicated to merging in vitro immunology research with bioinformatics to generate new therapeutics for cancer and autoimmune diseases as well as new vaccines for infectious diseases such as HIV, TB, and hepatitis. T cell epitope mapping, the selection of target peptides from any protein sequence, is a powerful resource for the development of novel protein therapeutics. EpiVax research shows that peptides chosen by EpiMatrix(TM) software are highly likely to provoke an immune response when presented to T cells. EpiVax tools can also accurately deimmunize proteins. For more information about EpiVax, please visit

About Tregitope

Tregitope is a set of peptides that induce the body's own natural regulatory T cells. When administered in conjunction with other antigens or protein immunogens, the response to these immunogens is diminished and altered if the antigen/immunogens are co-administered with Epi- 13. Preliminary in vitro and in vivo studies indicate that the modification of the immune response is due to the induction of natural T reg cells. Read the original article online at

About National Institute of Allergy and Infectious Diseases (NIAID)

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.

SOURCE EpiVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EpiVax receives JDRF program funding to develop diabetes drug using natural regulatory T-cells
2. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
3. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
4. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
5. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
6. Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation
7. Jon M. Huntsman Receives American Cancer Society Medal of Honor
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Kaiser Permanente Receives the Most Stars in California Office of Patient Advocates Annual Quality Report Card
10. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
11. Naviscan Receives 510(k) Clearance for Stereo Navigator(TM) - the First Commercially Available Breast PET-Guided Biopsy Feature
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of Excellence in the Life Sciences Initiative aimed at enhancing Purdue’s life sciences ... $2 billion “Ever True” capital campaign. , The investment will result in cohesive ...
(Date:10/13/2015)... West Palm Beach, FL (PRWEB) , ... October 13, 2015 , ... ... acquisition of Global Laser Vision of San Diego, California. With brands including The LASIK ... 3.3 million successful procedures, making it the nationwide leader in laser vision correction. , ...
(Date:10/13/2015)... N.J. (PRWEB) , ... October 13, 2015 , ... ... media enterprise focused on cancer patients, today announced a new partnership with the ... patients battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... beverage companies in the United States, today announced the release of its limited ... and new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a ... delivers innovative health programs and interventions via mobile devices that provide a framework ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... VEGAS , Oct. 13, 2015 VIVA ... of vascular medicine and intervention through education and research, ... annual conference,  VIVA 2015 . Sixteen trial results, featuring ... released for the first time on Monday and Tuesday, ... --> --> Since ...
(Date:10/13/2015)... , Oct. 13, 2015  Kay Elledge, ... and Fellow American College of Obstetrics and Gynecology ... evolve by establishing the Genuine Self Medical Laser ... and men.  In recognition of Breast Cancer ... special promotion for MonaLisa Touch treatments ...
(Date:10/13/2015)... PITTSBURGH , Oct. 13, 2015  Mylan N.V. (Nasdaq: ... at 5:00 p.m. ET host a conference call and webcast ... Company plc (NYSE: PRGO ; TASE) shareholders through Mylan,s ... by Mylan,s Executive Chairman Robert J. Coury , CEO ... --> --> Mylan ...
Breaking Medicine Technology: